Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10101270 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2PKML3MBTL1HTTRAB9A | |
| SCHEMBL8367896 | 0.84 | SMN1; SMN2 (0.36) | SMN1; SMN2PKML3MBTL1RAB9ATSHR | |
| SCHEMBL14273610 | 0.84 | SMN1; SMN2 (0.36) | SMN1; SMN2PKML3MBTL1RAB9ATSHR | |
| SCHEMBL14273611 | 0.84 | SMN1; SMN2 (0.36) | SMN1; SMN2PKML3MBTL1RAB9ATSHR | |
| SCHEMBL189842 | 0.84 | SMN1; SMN2 (0.36) | SMN1; SMN2PKML3MBTL1RAB9ATSHR | |
| SCHEMBL15107746 | 0.80 | NR1H2 (0.35) | SMN1; SMN2PKMALDH1A1CYP1A2NR1H2 | |
| SCHEMBL16478574 | 0.80 | NR1H2 (0.35) | SMN1; SMN2PKMALDH1A1CYP1A2NR1H2 | |
| SCHEMBL10083575 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2PKML3MBTL1HTTRAB9A | |
| SCHEMBL10083566 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2PKML3MBTL1HTTRAB9A | |
| SCHEMBL10083577 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2PKML3MBTL1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140010784-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-09 | — | — | US | disclosed |
| US-8486989-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-16 | — | — | US | disclosed |
| EP-1441720-B1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HEPATITIS C VIRUS NS3-NS4A PROTEASE, INCORPORATING A FUSED RING SYSTEM | VERTEX PHARMA (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402009-A1 | Inhibitors of serine protease, particularly hepatitis c virus NS3-NS4A protease, incorporating a fused ring system | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20080045480-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-7241796-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20030134889-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140010784-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | SERPINB1, PRSS1, SPINT2 | SMN1; SMN2 2528/4885PKM 3458/4885L3MBTL1 1032/4885 |
| US-20030134889-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | SERPINB1, PRSS1, SPINT2 | SMN1; SMN2 2528/4885PKM 3458/4885L3MBTL1 1032/4885 |
| US-20080045480-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | SERPINB1, PRSS1, SPINT2 | SMN1; SMN2 2528/4885PKM 3458/4885L3MBTL1 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.